title: Effect of rhBMP-2 and VEGF in a vascularized bone allotransplant experimental model based on surgical neoangiogenesis.
abstract: We have demonstrated survival of living allogeneic bone without long-term immunosuppression using short-term immunosuppression and simultaneous creation of an autogenous neoagiogenic circulation. In this study, bone morphogenic protein-2 (rhBMP-2), and/or vascular endothelial growth factor (VEGF), were used to augment this process. Femoral diaphyseal bone was transplanted heterotopically from 46 Dark Agouti to 46 Lewis rats. Microvascular repair of the allotransplant nutrient pedicle was combined with intra-medullary implantation of an autogenous saphenous arteriovenous (AV) bundle and biodegradable microspheres containing buffer (control), rhBMP-2 or rhBMP-2 + VEGF. FK-506 given daily for 14 days maintained nutrient pedicle flow during angiogenesis. After an 18 weeks survival period, we measured angiogenesis (capillary density) from the AV bundle and cortical bone blood flow. Both measures were greater in the combined (rhBMP-2 + VEGF) group than rhBMP-2 and control groups (p < 0.05). Osteoblast counts were also higher in the rhBMP-2 + VEGF group (p < 0.05). A trend towards greater bone formation was seen in both rhBMP2 + VGF and rhBMP2 groups as compared to controls (p = 0.059). Local administration of VEGF and rhBMP-2 augments angiogenesis, osteoblastic activity and bone blood flow from implanted blood vessels of donor origin in vascularized bone allografts.
authors.affiliation: Department of Orthopedics, University of São Paulo, Rua Dr Ovídio Pires de Campos, 333, Cerqueira Cesar, São Paulo, SP 05403-010, Brazil.
authors.forename: Tiago
authors.initials: T
authors.lastname: Mattar
authors.forename: Patricia F
authors.initials: PF
authors.lastname: Friedrich
authors.forename: Allen T
authors.initials: AT
authors.lastname: Bishop
mesh_terms: D000818:Animals; D055396:Bone Morphogenetic Protein 2 / Q000494:pharmacology*; D016025:Bone Transplantation; D018483:Diaphyses / Q000637:transplantation; D005269:Femur / Q000098:blood supply / Q000637:transplantation; D007166:Immunosuppressive Agents / Q000494:pharmacology; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D051381:Rats; D011994:Recombinant Proteins / Q000494:pharmacology; D012039:Regional Blood Flow; D016559:Tacrolimus / Q000494:pharmacology; D014184:Transplantation, Homologous; D042461:Vascular Endothelial Growth Factor A / Q000494:pharmacology*
chemical_list: C525718:BMP2 protein, human; D055396:Bone Morphogenetic Protein 2; D007166:Immunosuppressive Agents; D011994:Recombinant Proteins; D042461:Vascular Endothelial Growth Factor A; D016559:Tacrolimus